Enli Liu
Baylor College of Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Enli Liu.
Nature Genetics | 2002
Sonny O. Ang; Hua Chen; Kiichi Hirota; Victor R. Gordeuk; Jaroslav Jelinek; Yongli Guan; Enli Liu; Adelina I. Sergueeva; Galina Y. Miasnikova; David R. Mole; Patrick H. Maxwell; David W. Stockton; Gregg L. Semenza; Josef T. Prchal
Chuvash polycythemia is an autosomal recessive disorder that is endemic to the mid-Volga River region. We previously mapped the locus associated with Chuvash polycythemia to chromosome 3p25. The gene associated with von Hippel–Lindau syndrome, VHL, maps to this region, and homozygosity with respect to a C→T missense mutation in VHL, causing an arginine-to-tryptophan change at amino-acid residue 200 (Arg200Trp), was identified in all individuals affected with Chuvash polycythemia. The protein VHL modulates the ubiquitination and subsequent destruction of hypoxia-inducible factor 1, subunit α (HIF1α). Our data indicate that the Arg200Trp substitution impairs the interaction of VHL with HIF1α, reducing the rate of degradation of HIF1α and resulting in increased expression of downstream target genes including EPO (encoding erythropoietin), SLC2A1 (also known as GLUT1, encoding solute carrier family 2 (facilitated glucose transporter), member 1), TF (encoding transferrin), TFRC (encoding transferrin receptor (p90, CD71)) and VEGF (encoding vascular endothelial growth factor).
Journal of Biological Chemistry | 2006
Donghoon Yoon; Yves D. Pastore; Vladimir Divoky; Enli Liu; Agnieszka E. Mlodnicka; Karin Rainey; Premysl Ponka; Gregg L. Semenza; Armin Schumacher; Josef T. Prchal
Hypoxia-inducible factor-1 (HIF-1) regulates the transcription of genes whose products play critical roles in energy metabolism, erythropoiesis, angiogenesis, and cell survival. Limited information is available concerning its function in mammalian hematopoiesis. Previous studies have demonstrated that homozygosity for a targeted null mutation in the Hif1α gene, which encodes the hypoxia-responsive α subunit of HIF-1, causes cardiac, vascular, and neural malformations resulting in lethality by embryonic day 10.5 (E10.5). This study revealed reduced myeloid multilineage and committed erythroid progenitors in HIF-1α-deficient embryos, as well as decreased hemoglobin content in erythroid colonies from HIF-1α-deficient yolk sacs at E9.5. Dysregulation of erythropoietin (Epo) signaling was evident from a significant decrease in mRNA levels of Epo receptor (EpoR) in Hif1α-/- yolk sac as well as Epo and EpoR mRNA in Hif1α-/- embryos. The erythropoietic defects in HIF-1α-deficient erythroid colonies could not be corrected by cytokines, such as vascular endothelial growth factor and Epo, but were ameliorated by Fe-SIH, a compound delivering iron into cells independently of iron transport proteins. Consistent with profound defects in iron homeostasis, Hif1α-/- yolk sac and/or embryos demonstrated aberrant mRNA levels of hepcidin, Fpn1, Irp1, and frascati. We conclude that dysregulated expression of genes encoding Epo, EpoR, and iron regulatory proteins contributes to defective erythropoiesis in Hif1α-/- yolk sacs. These results identify a novel role for HIF-1 in the regulation of iron homeostasis and reveal unexpected regulatory differences in Epo/EpoR signaling in yolk sac and embryonic erythropoiesis.
American Journal of Human Genetics | 2003
Yves Pastore; Katerina Jedlickova; Yongli Guan; Enli Liu; James Fahner; Henrik Hasle; Jaroslav F. Prchal; Josef T. Prchal
The von Hippel-Lindau (pVHL) protein plays an important role in hypoxia sensing. It binds to the hydroxylated hypoxia-inducible factor 1 alpha (HIF-1 alpha) and serves as a recognition component of an E3-ubiquitin ligase complex. In hypoxia or secondary to a mutated VHL gene, the nondegraded HIF-1 alpha forms a heterodimer with HIF-beta and leads to increased transcription of hypoxia-inducible genes, including erythropoietin (EPO). The autosomal dominant cancer-predisposition von Hippel-Lindau (VHL) syndrome is due to inheritance of a single mutated allele of VHL. In contrast, we recently showed that homozygous germline 598C-->T VHL mutation leads to Chuvash polycythemia (CP). We subsequently found VHL mutations in three unrelated individuals unaffected with CP, one of whom was compound heterozygous for the 598C-->T mutation and another VHL mutation. We now report seven additional polycythemic patients with VHL mutations in both alleles. Two Danish siblings and another American boy were homozygous for the VHL 598C-->T mutation. Three unrelated white Americans were compound heterozygotes for 598C-->T and another VHL mutation, 562C-->G in two and 574C-->T in the third. Additionally, a Croatian boy was homozygous for a 571C-->G VHL mutation, the first example of homozygous VHL germline mutation causing polycythemia, other than the VHL 598C-->T mutation. We have not observed VHL syndrome-associated tumors in polycythemic subjects or their heterozygous relatives; however, this will need to be evaluated by longitudinal studies. Over all, we found that up to half of the consecutive patients with apparent congenital polycythemia and increased serum Epo we have examined have mutations of both VHL alleles. Those findings, along with reports of CP, underscore that VHL mutations are the most frequent cause of congenital polycythemia and define a new class of polycythemic disorder, polycythemias due to augmented hypoxia sensing.
Clinical Immunology | 2007
Zeyu Xiong; Yan Yan; Enli Liu; Richard T. Silver; Srdan Verstovsek; Fan Yang; Hong Wang; Josef T. Prchal; Xiao-Feng Yang
We attempted to determine whether the immune reactions elicited by aberrantly expressed testis antigens contribute to the beneficial responses to interferon (IFN)-alpha therapy and other therapies in patients with polycythemia vera (PV). We screened a human testis cDNA library using SEREX (serological analysis of tumor antigens by screening an expression cDNA library with sera from three patients with PV who had undergone IFN-alpha-induced or other therapeutics-induced remission). We identified two novel PV associated tumor antigens, PV65 (eIF-2alpha) and PV13 (protamine 2). These 2 antigens elicited IgG antibody reactions in a subset of PV patients but not in healthy donors, suggesting that they are authentic tumor antigens. Increased phosphorylation of PV65 in response to stimulation of IFN-alpha, and upregulation of PV13 in tumor cells might enhance their abilities in elicitation of immune reactions in patients. These findings provide new insights into the mechanism underlying the regulation of the self-antigen repertoire in eliciting anti-tumor immune reactions in patients with polycythemia vera, and suggest their potential as the targets of novel immunotherapy.
Experimental Hematology | 2007
Roberto H. Nussenzveig; Sabina Swierczek; Jaroslav Jelinek; Amos Gaikwad; Enli Liu; Srdan Verstovsek; Jaroslav F. Prchal; Josef T. Prchal
Blood | 2003
Yves Pastore; Jaroslav Jelinek; Sonny O. Ang; Yongli Guan; Enli Liu; Katerina Jedlickova; Lakshmanan Krishnamurti; Josef T. Prchal
Blood | 2005
Mingjiang Xu; Edward Bruno; Joseph T. Chao; Hongyu Ni; Valerie Lindgren; Rafael Nunez; Nadim Mahmud; Guido Finazzi; Steven M. Fruchtman; Uday Popat; Enli Liu; Josef T. Prchal; Damiano Rondelli; Giovanni Barosi; Ronald Hoffman
Blood | 2004
Enli Liu; Melanie J. Percy; Christopher I. Amos; Yongli Guan; Sanjay Shete; David W. Stockton; Mary Frances McMullin; Lydia A. Polyakova; Sonny O. Ang; Yves Pastore; Katerina Jedlickova; T. R. J. Lappin; Victor R. Gordeuk; Josef T. Prchal
Haematologica | 2005
Mc Bento; Kt Chang; Yongli Guan; Enli Liu; G Caldas; Richard A. Gatti; Josef T. Prchal
Experimental Hematology | 2007
Amos Gaikwad; Roberto H. Nussenzveig; Enli Liu; Stephen Gottshalk; Ko-Tung Chang; Josef T. Prchal